The first steps have begun to find Petplan and The Veterinary Business Journal's Practice Manager of the Year for 2012.
Nominations are now being sought for the most accomplished UK practice managers and recommendations are welcome from any member of the veterinary team.
Three finalists will be chosen and the winner announced at the annual Petplan Veterinary Awards in April 2012.
Robin Fearon, editor of the Veterinary Business Journal, said: "It is a distinct pleasure to launch the awards programme each year knowing that at the end of it we will be able to announce another winning practice manager.
"These awards are so important in promoting the role and highlighting the crucial part that managers play in practice strategy and success - we can't wait to see your nominations."
Judges will assess candidates' applications and choose the three finalists based on their competency in areas such as staff development, financial strategy and marketing initiative.
Last year's winner Denise Coston is practice manager at Castle Veterinary Surgeons in County Durham. She said: "Winning this award has meant a lot to me because it makes you feel valued. I would say to anyone thinking of nominating their practice manager: 'just do it'.
"The role of practice manager varies in each practice and can be hard to quantify with specific measures, but it means a lot to celebrate someone getting it right. It is an excellent way to promote the role of practice manager and it is great to get recognition alongside vets and nurses."
This award is supported by the Society of Practising Veterinary Surgeons and the Veterinary Practice Management Association.
As well as a plaque commemorating their achievements, the winner will once more receive one year's free membership to the VPMA.
Nominations for this year's award close on 10 February 2012. Application packs are available from: Jackie Morrison, The Veterinary Business Journal, Olympus House, Werrington Centre, Peterborough PE4 6NA, or e-mail jackiemorrison@vbd.uk.com.
Alternatively visit www.vetsonline.com/ to download yours direct.
The new pass offers both physical and virtual tickets so that the practice rota doesn't have to stop any member of the team from attending.
BEVA says the new tickets also offer a saving of up to £113 per vet.
David Mountford, Chief Executive of BEVA said: “We know that not every vet at a practice can attend congress every year because someone is always going to have to stay behind and work.
"So, by offering a mix of physical and virtual tickets in the pass it means those staying at home to look after the practice can still benefit from the live stream as well as the six-month access to all the lectures afterwards.
"Congress always contains plenty of relevant and dedicated content for nurses, so the pass obviously includes nurse tickets too.”
Practice Passes are available for BEVA members in three packages: small (£599), medium (£1,333) and large (£2,666).
Individual early bird BEVA member prices are £499 for vets and £187 for vet nurses for all three days (with concessions available for those in their first three years’ post-graduation or on a lower salary).
Practice Passes and early bird tickets are available to purchase until Monday 1 August 2022.
Day tickets are also available.
Virtual tickets are £199 for vets and £40 for nurses.
For more information, or to book tickets, visit http://www.bevacongress.org
Pfizer Animal Health has launched PrintRoom, an online printing service to help equine practices deliver high quality communications to their clients, to support the company's Equip range of equine vaccines.
PrintRoom can be used to produce customised vaccination reminder cards, invitations, letterheads, stable name sheets, and more.
You can choose from a palette of designs, images and colours and can also upload your own logos and images to tailor your client communications to your preferred style.
PrintRoom has a MailMerge option to pre-address all your mailings and you can pay for postage and set the date of despatch online, to help ensure boosters are administered on time and passports stay up to date.
Paul Blanc, Equine Brand manager at Pfizer said: "Good communication with your clients plays a vital role in maintaining vaccination compliance and retaining and gaining business. Our print room service makes it easy to produce a broad range of customised practice marketing materials to a very professional standard that stand out from the crowd."
For further information visit http://www.pfizerprintroom.com/, call 0845 6027439 or contact your Pfizer Account Manager.
An international group of scientists has published new results that herald a breakthrough in finding a vaccine against the most commonly diagnosed infectious disease of horses, strangles.
UK experts from the Animal Health Trust collaborated with scientists from the Swedish University of Agricultural Sciences (SLU), the Karonlinska Institutet Medical University and Intervacc AB, on the project - the results of which could benefit humans as well as animals.
Professor Andrew Waller, Head of Bacteriology at the AHT, said: "We have been working towards developing a vaccine for 7 years, and finally it seems as if all the hard work is paying off. We've already developed better ways of diagnosing exposure to the infection, and now, with the success of creating a safe and effective vaccine, it looks as if we're finally bringing together the tools necessary to eradicate this terrible disease."
The vaccine consists of seven different Streptococcus proteins and results from early tests published in PLoS Pathogens have been incredibly positive showing a high level of protection and no side effects. It is hoped that the strangles vaccine could be commercially available in the near future.
Streptococcus equi, the bacterium that causes strangles, shares 80 per cent identity with Streptococcus pyogenes - the leading cause of bacterial pharyngitis, tonsillitis and rheumatic fever in humans, which kills thousands of people each year. Scientists hope that the knowledge gained through developing the strangles vaccine will also help in developing vaccines to combat these human conditions.
Research leader, Professor Bengt Guss of SLU, said: "This is a most exciting project, where research is generating new applications and knowledge that can be used to develop vaccines against these important bacteria. This is particularly important considering the increased number of infectious diseases caused by antibiotic-resistant bacteria."
The vaccine development work was only made possible thanks to information from the Streptococcus equi genome sequencing project funded by The Horse Trust.
The Horse Trust's Chief Executive Brigadier Paul Jepson, said: "We are absolutely delighted that by pulling apart the genome of this plague of the horse world scientists have generated a truly safe and effective strangles vaccine. That this work could also benefit other animal and human health is beyond our wildest hopes."
Full text of the research findings can be found in PLoS Pathogens online at http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000584
According to the company, information on best worming strategies for foals and yearlings remains largely anecdotal, making it difficult to develop a clear plan for this age group. Zoetis veterinary surgeon Wendy Talbot has therefore reviewed the recent literature to develop an eight-point plan.
Explaining the guidance, Wendy writes:
Foals and yearlings are usually more susceptible to worms than are adult horses because they have had little chance to develop any immunity. They are more vulnerable to related diseases and tend to have higher egg shedding, which increases the risk of infection. The main parasitic culprits in the UK for foals less than six months of age are large roundworms (ascarids). In older foals and weanlings, small and large strongyles, tapeworms (and pinworms) are the main considerations.1 Yearlings may also have a second wave of large roundworm infection at 8-10 months of age.2 Any control strategy will need to take into account the individual circumstances such as stocking density, pasture management and previous disease history.
Guidelines for parasite control in foals suggest a first treatment with fenbendazole at 2-3 months of age, targeting large roundworm, followed by another treatment at 5-6 months. Alternatively, pyrantel may be considered for these doses; however, there may be resistance in some areas and foals with large adult ascarid burdens may be at higher risk of intestinal rupture when this drug is used.4 At weaning (approximately six months of age), it is advisable to perform a faecal worm egg count (FWEC) to determine if treatment for strongyles is also required; the macrocyclic lactone anthelmintics (ivermectin or moxidectin) are expected to have the highest efficacy. At 9 and 12 months of age treatment for stronglyes and a larvicidal dose for encysted stages of small strongyles (moxidectin or a 5 day course of fenbendazole) are indicated. A tapeworm treatment should be included with one of these doses.2,3
For yearlings, two methods have recently been proposed for worm control: the first involves using faecal worm egg counts (FWECs) at more frequent intervals than for adults to guide dosing for strongyles in the grazing season.1 The second suggests three baseline treatments targeting strongyles in spring, summer and late autumn, with FWECs in between to identify and treat any still shedding high numbers of eggs, up to a maximum of six treatments per year.2 Macrocyclic lactones have the highest expected efficacy against small strongyles and should form the basis of treatments; however, pyrantel can be considered for some treatments where it has been shown to have continued efficacy. Both strategies include a larvcidal treatment for encysted small redworm combined with testing or treating for tapeworm in late autumn. The inclusion of one or two doses of a macrocyclic lactone each year (usually already used for small strongyle control) should be sufficient to prevent large strongyle related disease.3
The wide differences in the circumstances of foals and yearlings, together with geographical variations in resistance patterns and a lack of consensus on best practice in this group means it is not possible to define a single approach to a worming plan. An important point to note is that FWECs may give surprising results because higher counts are generally seen in youngstock.
Eight ways to keep clients' youngstock worms controlled:
For further information on worming together with some equine specific CPD visit: https://blog.vetsupportplus.com/
The event is held every four years and hosted alternately by BEVA and the American Association of Equine Practitioners (AAEP).
It offers the opportunity for equine vets to absorb and digest the latest knowledge, clinical practice and scientific advances in the treatment and prevention of colic, from the world’s leading international equine gastroenterology experts.
Held over 2.5 days, the symposium comprises numerous 12-minute oral presentations on a range of topics including surgical techniques, treatment, parasitology, gastric ulceration, endotoxemia, pharmacology of intestinal motility, colic complications, epidemiology, physiology of digestion, the intestinal microbiome and metabolomics.
Each session will be followed by three minutes for questions and discussion.
Poster sessions on the first two days will cover ground beyond the oral presentations and delegates will be able to review and discuss the work with presenters.
There will also be opportunities to network with other equine vets, researchers and professionals.
Clinicians and scientists have until 1 February 2024 to submit abstracts of recent work that they wish to present at this meeting.
The scientific committee will consider abstracts on all aspects of equine gastroenterology, including basic science research and reports of clinical cases or novel approaches to treatment.
The abstract submission form is here: https://form.jotform.com/230473925626359
Tickets cost £475 (with a concessionary rate of £235 for post graduate students and interns) and includes a drinks reception on both 10th & 11th, an evening buffet and Ceilidh on 11th and lunch on 11th & 12th.
Further information and booking details can be found here: https://www.beva.org.uk/Education/CPD/Event-Details/eventDateId/1740
Merial Animal Health has announced that the duration of immunity for the tetanus component of Proteqflu-Te has been extended to 2 years.
Merial's Veterinary Technical Manager Kevin Whelan said: "This is a welcome new addition to the label claims for this advanced vaccine, which is the only equine flu vaccine in the UK to contain a recently updated influenza virus strain. The updated strain, innovative canarypox vector technology and now the extended tetanus duration of immunity claim make the vaccine an excellent choice for vets in the UK"
Merial says Proteqflu-Te can now be used on an alternate year basis in combination with the company's other flu vaccine, Proteqflu, which does not contain tetanus toxoid. The one year duration of immunity for the influenza component remains unchanged.
Please contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
The new packaging uses fewer plastic components and a new cardboard box.
Sabrina Jordan, Virbac’s Equine Product Manager said: "The new cardboard component is a substantial step forward making the new packaging more environmentally friendly."
She added: "This new Equimax packaging has a fresh new look and is now available at wholesalers."
Wiley has announced the joint online publication of a special issue of 22 ophthalmology papers from Equine Veterinary Journal, Equine Veterinary Education and Veterinary Ophthalmology.
Clinical equine ophthalmology: The current state of the art brings together papers on some of the most significant advances in equine clinical ophthalmology into a single issue to make them more readily available to a wider audience. The issue contains information of direct relevance to all sectors of the veterinary profession from general practitioners and specialists to researchers, surgeons and students, covering common diseases, surgical procedures and outcomes.
The new publication was devised and compiled by a panel of guest editors comprising Mary Lassaline, member of the Veterinary Ophthalmology Editorial board and Veterinary Ophthalmologist in the Department of Surgical and Radiological Sciences at UC-Davis School of Veterinary Medicine, California, David A. Wilkie, Editor of Veterinary Ophthalmology and Professor at Veterinary Clinical Sciences Comparative Ophthalmology Ohio State University, Tim Mair, Editor of Equine Veterinary Education based at Bell Equine Veterinary Clinic, Kent and Celia M Marr, Editor of Equine Veterinary Journal, based at Rossdales, Newmarket.Mary Lassaline said: "The goal was to provide broad access to the most current information applicable to every stratum of the equine veterinary profession. Subsequently, a salient feature is that many of the papers included are collaborations between veterinary ophthalmologists with a special interest in horses, equine practitioners with a special interest in ophthalmology, private practitioners and those in academia, and academicians from different institutions."
Subjects covered include seven papers on new approaches to the diagnosis and treatment of ulcerative and non-ulcerative keratitis in the horse. There are three articles on novel approaches to corneal surgery and a further three on corneal neoplasia. Six papers provide valuable data regarding long-term outcomes following surgical intervention for Equine Recurrent Uveitis (ERU), glaucoma, and cataracts. Finally, three articles present new information regarding retinal and orbital disease.
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "The key purpose of the EVJ is to disseminate information to help the enhancement of specialist knowledge at every level of the veterinary profession. By collating the most important and up-to-date ophthalmology research into one easy resource the new special issue does exactly that."The ophthalmology special issue is available free online at: http://bit.ly/1bi0RG0
Veterinary practices are being urged to raise awareness of summer skin conditions, such as sweet itch, following research carried out by Elanco Companion Animal Health, distributor of Cavalesse, which revealed that vets only tend to be consulted after horse owners have tried to manage the condition themselves (73%), or if the clinical signs have become severe (67%), potentially leading to major welfare implications.
According to the research, this is despite the fact that over half (55%) of owners of a horse with sweet itch showed concern that their horse will suffer, and nearly half being stressed about the way the condition will affect it (47%). While many horse owners are fairly knowledgeable about the causes of sweet itch and its clinical signs, over a quarter of respondents (26%) did not start managing the condition before the midge season in the spring, which may make managing the condition more frustrating. Nearly a third (31%) stated that they had to curtail their activities with their horse due to welfare, aesthetic and behavioural issues, such as head shaking, rubbing, unpredictability and aggression.
Ed Whittle, technical consultant at Elanco Companion Animal Health said: "86% of those questioned considered sweet itch to be a very serious welfare issue if left untreated, with the worst aspects of the condition being the suffering and distress caused by the constant irritation which affects the quality of life of the horse. Over half (55%) felt that sweet itch had adversely affected the behaviour of their horse, making them difficult to handle or ride. Veterinary practices should be proactively talking to their clients about summer skin conditions such as sweet itch to help alleviate the suffering and distress caused by this frustrating disease."
Elanco says it will be joining forces with the British Horse Society (BHS), The Blue Cross, The Horse Trust, Redwings Horse Sanctuary and World Horse Welfare (WHW) to raise awareness of summer skin conditions, such as sweet itch, during Sweet Itch Awareness Month (SIAM) in March. The campaign will highlight the preventative measures that should be carried out to help alleviate sweet itch and the importance of management of the condition before the start of the midge season in the spring.
Lee Hackett, head of welfare at the BHS, said: "The results of this survey show just how important raising awareness of sweet itch is. All of us, whether we are welfare organisations or vets, need to play our part in educating owners about sweet itch in the hope that they will seek expert advice at an earlier stage and reduce the number of horses that suffer as a result of this condition."
Kerry Taylor, education officer at The Blue Cross, said: "The Blue Cross is pleased to be supporting the sweet itch campaign to raise awareness of the physical and mental impact this condition has on horses. During our May 2011 National Equine Health Survey, skin problems came out the top syndrome affecting horses, and we continue to see many horses coming into our care suffering from sweet itch. Prevention and early treatment is key to managing the potentially debilitating condition."
For further information on sweet itch, Sweet Itch Awareness Month or Cavalesse, please visit http://www.fidavet.com/, or contact Elanco Companion Animal Health, Lilly House, Priestley Road, Basingstoke, RG24 9NL, 01256 353131.
Reference
Sweet itch - effect on horse and owner. Mo Gannon & Associates. Web survey in November 2011. 351 responses - owners who have owned horses with sweet itch in the last two years.
David says that whilst he was out there, he was told about attacks by Russian forces on stables in Bucha, Irpin and other equestrian premises north of Kyiv.
Ukraine vet Anatoly Levitsky who is working in Kyiv, said: “Not very big horse club was not far from Borodianka and owners were using their horses for hippotherapy of children with different pathologies.
"When war started, the lady who owned the stable and her child emigrated to Poland and her husband was conscripted into Ukrainian army.
"When Russian bandits in army uniform came to the village, they set fire to the stable and started shooting the horses that tried to escape.”
“Some horses ran away, others were wounded, and some were burned down.
"After the building was burned, Russian soldiers went away and horses that escaped were wandering around the village and trying to find the feed.
"Step by step, people living in the village collected the horses and keep one or two horses in their yards.”
David said: “It is hard to understand what could motivate anyone to perform these deliberate acts of cruelty.
"Random shootings, stabbings and burnings are widely reported and pictured on social media, we have no idea how many horses are dead and how many injured, but it has to be a significant number.
“Some of the lorry drivers I have met coming out have been shot at, shelled and beaten up, evacuating surviving horses.
"They are taking risks that we would consider totally unacceptable to move animals out and supplies in.
"I have nothing but admiration for the bravery of the Ukrainian people.”
“Ever conscious that there is an equal humanitarian need you feel very small and rather cowardly that you aren’t permitted to go into Ukraine to help the people and animals that require treatment.”
The British Equine Veterinary Association and American Association of Equine Practitioners are working together to support vets in Ukraine.
They say that they are not allowed to provide direct practical help, but they are doing what they can to get veterinary and humanitarian supplies to the vets they are in contact with.
They are also working to establish safe stables in the West of Ukraine to get horses and their owners away from likely areas of combat in the East.
Previously people have had no option but to turn horses into the woods prior to fleeing or they have stayed to look after their animals despite the risks to themselves.
BEVA, in association with the British Equestrians for Ukraine Fund, is calling for urgent support to help fund veterinary treatment, supplies and the safe relocation of Ukraine’s endangered horses.
To do this they need your urgent support. To make a donation visit https://www.worldhorsewelfare.org/support-us/appeals/british-equestrians-for-ukraine-fund.
To find out more you can listen to a podcast from David Rendle here https://beva.podbean.com/e/bevapod-episode-13/
Photo: Stabling reportedly burned down by Russian soldiers
Ridgeway Research Ltd has a surplus supply of short-dated Target IgG kits on special offer.
The kits are to test for passive transfer to foals via colostrum. Each kit contains 20 tests and normally costs £74. They have been reduced to £20 to clear. The use by date is end February 2010.
If you are interested, please email jo@ridgewayresearch.co.uk, or ring 01594 530809 for further information.
Intervet/Schering-Plough Animal Health has announced that it is re-introducing Equilis StrepE, the only strangles vaccine for horses in Europe. The vaccine was voluntarily withdrawn from the market in 2007 for stability reasons.
Equilis StrepE, which has already been relaunched in the Netherlands, is now scheduled to arrive in Italy in September and the United Kingdom in October this year. Further re-launches in European countries are scheduled later in 2010 and beyond.
According to Intervet/Schering-Plough, three years of additional research and development have resulted in several improvements to the vaccine, including a better manufacturing process to ensure that the product maintains its characteristics throughout its shelf-life. A more user-friendly applicator has been developed, which enables the needle to slot into place, thereby making it easier to administer the vaccine.
Equilis StrepE is administered through a submucosal injection in the upper lip of the horse and provides immunity for three months following two initial injections, four weeks apart. The vaccine significantly reduces clinical signs of strangles and occurrence of lymph node abscesses in horses that are at risk of infection.
Dr. Peter Daels, veterinarian at the Keros Insemination and Embryo Transfer Center in Beselare (Belgium) said: "In our recipient embryo transfer herd, we have used this strangles vaccine on over 500 mares. After a few applications, the vaccine was easy to administer and did not cause any serious side effects. Despite a steady flow of new horses, only eight cases of strangles were noted - all were mild and most were newly acquired horses that had apparently been exposed shortly before vaccination. I believe that the vaccine provided solid protection against the disease, reduced the severity of clinical cases and eliminated the risk of a widespread outbreak in our herd."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering Plough Animal Health said: "The re-launch of Equilis StrepE in Europe is an important milestone in our efforts to fully meet the needs of our customers in the equine industry. We continue to work in a very intense and comprehensive way to ensure adequate supply of our equine vaccine range".
Ceva Animal Health has highlighted a new study which revealed that the use of the opioid buprenorphine, the active ingredient in Vetergesic, before equine elective general anaesthesia and surgery resulted in better post-operative analgesia than butorphanol, without causing further physiological disruption than is normally expected of general anaesthesia in horses.
The prospective, randomised and blinded multicentre study, conducted by Dr Polly Taylor VetMB MA PhD DVA DipECVAA MRCA MRCVS, an RCVS Specialist in Veterinary Anaesthesia, compared the degree of post-operative pain and physiological variables in horses following premedication with either buprenorphine or butorphanol in a general clinical setting. The study included 89 healthy adult horses from six UK equine veterinary clinics admitted for routine elective surgical procedures.
Ceva says that butorphanol is often used in equine procedures due to familiarity and its value for enhancing alpha2-induced sedation, but that it is probably the least effective opioid as an analgesic. There is also a common perception that butorphanol has less impact on locomotor stimulation and depression of intestinal motility than other opioids. This is likely to have contributed to the almost exclusive use of NSAIDs to manage pain in the post-operative period.
To view the full study, visit http://onlinelibrary.wiley.com/doi/10.1111/evj.12442/abstract. For details on Ceva's analgesic product range, email analgesics-group@ceva.com or call 01494 781510.
Horiba Medical has announced it is the official exclusive UK distributor of the fully automated Vet abc Plus+ veterinary haematology analyser from scil animal care company GmbH, Germany.
According to the company, the compact Vet abc Plus+ provides a complete blood count (CBC), including 4-part white blood cell (WBC) differential, from only 10 µl of EDTA whole blood, in only 60 seconds.
The Vet abc Plus+ provides pre-installed settings to analyse samples from dogs, cats, horses, rabbits, mice, rats, cattle, pigs and sheep. For dogs, cats and horses, the Vet abc Plus+ provides a 4-part WBC differential blood count, including a differentiation of the leucocytes to identify lymphocytes, monocytes, granulocytes and eosinophils. Results are available in 60 seconds on screen or can be automatically printed out and transferred to the practice information system or clinical notes. For ease-of-use, the Vet abc Plus+ also incorporates a self-contained reagent and waste system which provides a clean operation whilst being easy to replenish.
Borne from an existing manufacturing partnership, scil and HORIBA Medical already have over 6000 veterinary haematology analysers placed globally. Horiba says the new UK distribution agreement enables UK veterinary professionals to not only procure the Vet abc Plus+ analyser, but also receive expert service and support directly from the manufacturer HORIBA Medical and its team of UK specialists.
For more information, visit: www.horiba.com/uk/medical
The University of Liverpool’s Philip Leverhulme Equine Hospital has installed a standing equine MRI scanner from Hallmarq Veterinary Imaging.
The traditional method for detecting equine lameness is subjective, using expert visual evaluation of gait to identify the presence or absence and degree of asymmetries. The lame horse is described as having a disorder, defect or loss of function and this clinical diagnosis has associated welfare implications if the horse is still asked to perform.
The article explains how advanced computer technology is starting to change all this. Optic motion capture or the use of inertial measurement units (IMUs) is now enabling the detailed study and quantification of the horse’s gait; objective assessment against preset thresholds. The paper points out that while these digital systems can overcome the temporal and spatial limitations of the human eye they simply rely on one or a number of set gait parameters to decide about lameness and this can present obstacles.
Thresholds are forcibly based on a limited reference population, which doesn’t adequately reflect the millions of horses in the world. The individual environmental and mental conditions for each horse and its day-to-day gait variations are also not accounted for. On this basis to use the term ‘lame’ because a horse demonstrates a subtle gait alteration, causing it to fall below the threshold, could be inappropriate, particularly as it may not affect the horse’s welfare in any way.
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "An important first step is for researchers and clinicians to start to discriminate clearly between 'asymmetry' and 'lameness' and not to use these as interchangeable terms when interpreting gait analysis data. Asymmetry is often, but not always, a hallmark of lameness, but is not a clinical term, whereas lameness is."
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
The BEVA Trust is the Association’s philanthropic arm and in 2015 members decided that it should provide support for voluntary projects to help improve knowledge and welfare.
Since then volunteers have been rolling up their sleeves to help out with castration and welfare clinics in the UK and veterinary training schemes around the world.
Over the past 12 months a total of 42 vets and vet nurses have volunteered their time at seven BHS Education and Welfare Clinics throughout the UK.
They have helped microchip, passport, vaccinate and castrate horses recognised by Welfare Officers as needing help.
So far 598 horses and ponies have received passports and 302 been castrated.
The Trust has seen a further ten volunteers travel across the globe, working on projects in Cambodia, the Gambia, Honduras, Kiev, Nicaragua and the Ukraine.
BEVA President Vicki Nicholls said: "We thank all of the volunteers that make our Trust such a success, with special mention to Luke Edwards from the University of Liverpool and Alice Horne from Ddole Road Veterinary Clinic who have both volunteered at four clinics. We must also remember the good work of our industrious BEVA Council members and our excellent speakers at Congress this September, who are all volunteers."
For further information on BEVA Trust volunteer projects email lara@beva.org.uk to be added to the BEVA Trust mailing list.
The charity will be carrying out a study about the disease in collaboration with the Universities of Liverpool and Nottingham. However, because funding for research is limited, and because researchers want it to answer questions around PPID that owners and veterinary surgeons actually want to know, they are asking for your suggestions.
The AHT says that it wants to provide owners and vets with practical and applicable advice that will improve the wellbeing of their horses, based on scientific evidence. So whether that’s a question around how the disease is diagnosed, the best way to treat it or what the long term prognosis is, now is your chance to have your say.
If you own or care for a horse/pony with PPID or are a veterinary surgeon that treats them (or you have done in the past) please visit: www.aht.org.uk/PPID, to take part.
If you have any questions, contact the Project Investigator Becky Tatum by email: becky.tatum @aht.org.uk or by telephone: 01638 751000 Ext. 1241
From early 2025, all vets, nurses and technicians will be required to wear a hard hat in the vicinity of a horse, pony or donkey – whether in practice, on a yard, or at a client’s premises.
It follows a three-year research project collaborating with the University of Liverpool which revealed that 90% of veterinary clinicians have experienced an injury during their career.
It is hoped that the move will reduce injuries to the head – one of the most common traumas to be suffered by equine vets identified by the research, usually sustained when examining distal limbs. CVS says that in the US, equine vets sustain on average eight serious injuries during their career, making it the second highest profession for non-fatal injuries.
The University of Liverpool research found that over 25% of equine vet injuries have led to hospital attendance. Dr. John Tulloch, Lecturer and European Specialist in Veterinary Public Health at the University of Liverpool, who led the research, said: “Vet visits are not an ‘everyday activity’ for a horse.
"As a result, many horses will be on heightened alert, and some may be more prone to unpredictable behaviour. “Vets are often in a vulnerable situation when examining a horse.
"And it’s difficult to pick up on a horses’ signals, especially when examining areas such as distal limbs. “Our research found that many injuries happen when a horse kicks or pushes a person over and the person’s head makes impact with the ground.
"So, wearing a hard hat will be a big step towards preventing traumatic head injuries if this were to happen.” Sophie Ignarski, Equine Director at CVS said: “All of our clinicians are at risk in their day-to-day work – whether they are newly qualified or very experienced.
"Other colleagues including nurses, vet techs and patient care assistants are similarly vulnerable. “We decided to make wearing of hard hats mandatory in order to protect all of our colleagues and minimise the potential risk of head injury, understanding it can never be fully eliminated.
"We recognise that this policy shift represents a degree of change but hope that it serves to further support and progress the equine veterinary industry more widely. “Our policy is evidence-based, utilising three years of rigorous research, and we will continue our efforts in the future to grow our knowledge and understanding of this important area.
"By doing so, we join other industries – such as construction – who have already adopted similar changes to the extent they are now established in their culture.”
https://www.sciencedirect.com/science/article/pii/S0167587725001266
Four separate studies are included in the collection, reporting novel risk factors for the disease, identifying key differences between EGS and botulism (questioning the hypothesis that EGS is caused by neurotoxins from Clostridium botulinum), reporting a novel diagnostic technique and showing the value of monitoring weight loss to help predict whether individual horses with chronic EGS are likely to survive.
The publishers say that despite more than 100 years of research, supported predominantly by the The Moredun Foundation Equine Grass Sickness Fund (www.grasssickness.org.uk), the cause of EGS remains unknown. Since it almost exclusively affects grazing horses, a pasture derived neurotoxin is implicated. EGS causes gut paralysis as a result of damage to parts of the nervous system that control involuntary functions. Acute and sub-acute EGS is invariably fatal while around 55% of chronic cases can survive and return to a useful working life. The UK has the highest incidence of EGS in the world; indeed it is estimated that the disease kills between 1 and 2% of horses in the United Kingdom annually. Cases are more common in spring.
In terms of risk factors, the study ‘Equine grass sickness in Scotland: A case-control study of environmental geochemical risk factors’ suggests that the high incidence of the disease in Eastern Scotland may be partly associated with the particular composition of macro and trace elements in the soil in the fields on which horses graze. Further work is required to determine whether interventions to alter concentrations of particular elements in soil could potentially reduce the risk of EGS.1
A second study identified key differences between EGS and botulism, which questions the currently favoured hypothesis that EGS is caused by neurotoxins from Clostridium botulinum, a bacterium which commonly inhabits soil. The study ‘Equine grass sickness, but not botulism, causes autonomic and enteric neurodegeneration and increases soluble N-ethylmaleimide-sensitive factor attachment receptor protein expression within neuronal perikarya’ suggests that EGS is unlikely to be caused by neurotoxins from this bacterium and concludes that further investigation of an alternative cause for EGS is needed.2
While the majority of horses with EGS can be readily diagnosed by experienced veterinary surgeons, some cases present a diagnostic challenge. Indeed the only way to definitively diagnose the disease in a live horse is to demonstrate the characteristic degeneration of nerves within biopsies of the intestine. Unfortunately these biopsies can only be collected by performing abdominal surgery under general anaesthesia. In the study ‘Neuronal chromatolysis in the subgemmal plexus of gustatory papillae in horses with grass sickness’ characteristic degeneration of nerves was identified in small biopsies collected from tongues of EGS horses during post mortem examination. Examination of these biopsies accurately differentiated control horses from EGS cases. While further validation of this technique is required, it could potentially provide a relatively non-invasive method of confirming the diagnosis in a live horse.3
While around 55% of horses with chronic EGS survive, objective criteria for predicting survival of these cases are currently lacking. The study ‘Bodyweight change aids prediction of survival in chronic equine grass sickness’ reported that non-survivors had greater rate and magnitude of bodyweight loss than survivors. Survival prediction curves were published to allow veterinary surgeons and horse owners to use body weight data to help determine whether an individual horse with chronic EGS was likely to survive or die.4
Professor Bruce McGorum, Head of the Equine Section at the Royal (Dick) School of Veterinary Studies & Roslin Institute in Edinburgh, has been leading much of the research. He said: "Given that our recent research suggests that EGS is unlikely to be caused by neurotoxins from Clostridium botulinum we are now moving on to determine whether EGS is caused by ingestion of mycotoxins produced by pasture fungi. We are very pleased that The Horse Trust (www.horsetrust.org.uk) has provided funding for this three-year investigation."
Professor Celia Marr, Editor of the Equine Veterinary Journal said: “While the cause of equine grass sickness continues to evade us, these papers present an optimistic step in the right direction for the eventual prevention of this dreadful disease. It is only with the support of the Moredun Foundation Equine Grass Sickness Fund and more recently that of The Horse Trust that our world-leading veterinary researchers are able to continue to unravel the mystery.”
The EVJ equine grass sickness collection can be downloaded at http://bit.ly/2dC7Drr
References
The British Equine Veterinary Association (BEVA) has launched two guides to help veterinary professionals and their clients negotiate the complexities of equine insurance.
BEVA highlights that with up to 40% of horses becoming ill or injured in any one year and 25% of insured horses having a claim in any one year, vet fees insurance is a sensible way for horse owners to budget for unexpected healthcare costs.
The Veterinary Surgeon's guide to riding and sport horse insurance provides general guidelines to help vets understand the requirements and issues relating to equine insurance. It explains the three main types of insurance cover available: veterinary fees, death and permanent loss of use, as well as insurance recommendations for pre-purchase and pre-insurance vetting. The final section contains a jargon-busting guide to commonly used insurance terminology.
Complementing the vet guide is The BEVA leisure and sports horse Insurance Guide for horse owners, a handout for clients about to embark on taking out insurance. It covers the frequently asked questions relating to vets fees and death, including when and how to insure, the importance of pre-purchase vetting, exclusions and permanent loss of use.
Andrew Harrison, Junior Vice President of BEVA, said: "Whether a vet or a horse owner, understanding equine insurance can be intimidating for the best of us. The new guides should make it easier for you and your clients to understand the finer points of policies, premiums and claim protocols."
The guides can be downloaded from the BEVA website via the following links:
For additional information visit www.beva.org.uk
The British Veterinary Association has welcomed the European Commission's Action Plan on Antimicrobial resistance (AMR), launched yesterday on the eve of European Antibiotic Awareness Day.
The Action Plan sets out 12 actions:
However, the association has expressed concern that the Commission has given only qualified support for new antimicrobials for veterinary use. Carl Padgett, President of the BVA, said: "There is much to be applauded in this action plan. In particular the BVA supports the calls for more and better coordinated research, more responsible use of antimicrobials in human and veterinary medicine, and the development of diagnostic tools to quickly and accurately identify the right drug for the right bug.
"The use of antimicrobials in the treatment and control of animal diseases is essential and the BVA supports the strong messages in this plan. Any option for managing AMR must be firmly rooted in sound scientific assessment of the risk.
"While the report recognises the difficulties that have led to the hampering of research into new antimicrobials for veterinary use, we are concerned that there is only qualified support from the Commission for the development of these new medicines for animal use.
"Research into new antimicrobials should be supported in both human and veterinary medicine. We need to ensure the creation of a more predictable regulatory environment to encourage new products for animals to be brought to the market.
"Finally, while the BVA supports the need for a new regulatory framework any new regulations must not impede the ability of veterinary surgeons to prescribe and dispense medicines according to their clinical judgement."
Meanwhile, Jill Moss of the Bella Moss Foundation added her voice to those calling for responsible use of antibiotics, highlighting recent research from the Royal Veterinary College that has established a clear link between pets with MRSA infection and human hospital-associated MRSA. What is less widely recognised, she says, is that resistant bacteria can be passed from human to animal.
The charity is now calling on health and veterinary professionals to work together to achieve a reduction in resistant infections by raising awareness and promoting the responsible use of antibiotics.
MSD Animal Health's equine division has launched a new series of materials to support its Keeping Britain's Horses Healthy Campaign.
For veterinary practices, there's a Vet Reception Pack designed to help receptionists educate owners why they should vaccinate and the benefits of preventive healthcare.
For yards, there are posters giving guidance and advice on prevention of Infectious Respiratory Disease and the steps which should be taken to control a potential outbreak. They can be tailor made for an individual yard.
Peter Young, MSD Animal Health Equine Business Manager said: "Our first wave of support materials focused very much on equine vets and owners - helping raise awareness of the importance of preventive healthcare and driving owners towards vets for advice. This phase of materials helps support yard owners and receptionists, aiming to fill some of those communications gaps where advice and guidelines on individual horse's vaccination requirements and yard protocols can play a vital role in preventing the spread of disease and controlling outbreaks."
Keeping Britain's Horses Healthy is a national campaign to educate horse owners on endemic infectious disease, vaccination, herd immunity and the importance of preventative healthcare. It includes a range of educational materials for veterinary surgeries and direct to owners. The campaign is supported by a national PR, advertising and social media programme, together with a dedicated website www.healthyhorses.co.uk. The website, aimed at driving owners back to their veterinary practices, includes a vet finder, exclusively for equine practices, and healthcare information.
For full details of the launch programme, talk to your account manager, call 01908 685685 or visit www.healthyhorses.co.uk.